In This Article:
The 2024 Q4 earnings season has picked up notable steam this week, with the reporting docket stacked. Among the bunch of companies expected to report in the coming days include a few consumer staples titans such as Procter & Gamble PG, Johnson & Johnson JNJ, and Kimberly-Clark KMB.
See the Zacks Earnings Calendar to stay ahead of market-making news.
Let’s take a closer look at how each stacks up heading into their respective quarterly releases.
PG Sees Downward Revisions
PG shares have faced some turbulence over the past six months, down roughly 3% but modestly outperforming the Zacks Consumer Staples sector. Analysts have shown some bearishness for the quarter to be reported over the last several months, with the $1.86 Zacks Consensus EPS estimate down 2% over the period and suggesting 1% year-over-year growth.
Top line revisions have primarily followed the same path, with forecasted sales of $21.6 billion 0.7% higher than the year-ago figure.
Image Source: Zacks Investment Research
While growth is muted, the company’s gross margin has expanded nicely, leading to stronger profitability overall. Please keep in note that the chart is on a trailing twelve-month basis. It’s also worth noting that the company reaffirmed its current year guidance in its latest release, likely limiting any potential spooky surprises.
Image Source: Zacks Investment Research
The valuation picture here isn’t overly enticing, with the current 22.5X forward 12-month earnings multiple in line with the five-year median and beneath five-year highs of 26.7X. The PEG ratio works out to 3.5X, notably rich for the growth expected.
The stock sports a Style Score of ‘D’ for Value.
JNJ Margins Come Under Pressure
JNJ shares have also faced pressure over the past six months, down 2% but again outperforming the Zacks Consumer Staples sector by a fair margin. Similar to PG, analysts have shown slight bearishness for the release, with the $2.00 Zacks Consensus EPS estimate down modestly over the last several months and suggesting a 13% decline year-over-year.
Still, decent sales growth is forecasted, with JNJ’s top line expected to expand 5.3% year-over-year.
Image Source: Zacks Investment Research
However, the margins picture here has become quite negative, partly explaining the big profitability crunch and declining EPS. Positive commentary surrounding margins would be a major boost for the stock, perhaps sparking some bullish action.
Image Source: Zacks Investment Research
The valuation picture here is more enticing than PG, with the current 13.9X forward 12-month earnings multiple well beneath the 16.1X five-year median and 19.1X five-year highs. The PEG works out to 2.4X, somewhat steep but otherwise beneath the 2.7X five-year median.